Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
REGENXBIO Inc. (RGNX) had Stock-Based Compensation of $26.19M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$29.73M |
|
$-61.94M |
|
$5.72M |
|
$24.01M |
|
$82.14M |
|
$-52.41M |
|
$-9.53M |
|
$-61.94M |
|
$-61.94M |
|
$-61.94M |
|
$-61.94M |
|
$-61.94M |
|
$-61.94M |
|
$-52.41M |
|
$-46.10M |
|
51.69M |
|
51.69M |
|
$-1.20 |
|
$-1.20 |
|
| Balance Sheet Financials | |
$331.97M |
|
$107.52M |
|
$193.24M |
|
$525.20M |
|
$124.57M |
|
-- |
|
$239.18M |
|
$363.75M |
|
$161.45M |
|
$161.45M |
|
$161.45M |
|
50.62M |
|
| Cash Flow Statement Financials | |
$-71.67M |
|
$-53.41M |
|
$126.36M |
|
$59.56M |
|
$60.83M |
|
$1.28M |
|
|
Stock-Based Compensation |
$26.19M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.66 |
|
-- |
|
-- |
|
-- |
|
-- |
|
80.75% |
|
-176.27% |
|
-176.27% |
|
-- |
|
-208.32% |
|
-208.32% |
|
$-73.58M |
|
-- |
|
-- |
|
-- |
|
0.06 |
|
-- |
|
1.17 |
|
76.72 |
|
-38.37% |
|
-38.37% |
|
-11.79% |
|
-38.37% |
|
$3.19 |
|
$-1.42 |
|
$-1.39 |
|